Skip to main content

Table 3 SARS-CoV-2 sequence results for reported vaccine breakthrough cases and national genomic surveillance program from five states during January–March 2021

From: Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January–March 2021

SARS-CoV-2 lineages

Vaccine breakthrough case

[N = 155]

Genomic surveillance data

[N = 5738]

No

(%)

No

(%)

Variants of concern

    

 B.1.1.7 (Alpha)

41

(26)

1,649

(29)

 P.1 (Gamma)

2

(1)

29

(1)

 B.1.351 (Beta)

0

(0)

11

(< 1)

 B.1.617.2 (Delta)

0

(0)

1

(< 1)

Other lineages

112

(72)

4,048

(71)

  1. Chi-square p-value > 0.05 for differences between the SARS-CoV-2 sequence data for reported vaccine breakthrough cases and sequence data reported from the five states to the national genomic surveillance program